Page last updated: 2024-11-06

zopiclone and Chronic Disease

zopiclone has been researched along with Chronic Disease in 25 studies

zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007
zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"To determine the long-term efficacy of eszopiclone in patients with chronic insomnia."9.10Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. ( Amato, DA; Caron, J; Krystal, AD; Laska, E; Roth, T; Walsh, JK; Wessel, TC, 2003)
"6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study."6.65Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1983)
"Tolerance or rebound insomnia was not reported."6.43Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. ( Najib, J, 2006)
"Alprazolam is a triazolobenzodiazepine derivative used as a tranquilizer."5.37Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. ( Antonescu, A; Bogdan, M; Dobjanschi, L; Moş, I; Mureşan, M; Muţiu, G; Zdrîncă, M, 2011)
"6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study."5.26Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1982)
"To determine the long-term efficacy of eszopiclone in patients with chronic insomnia."5.10Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. ( Amato, DA; Caron, J; Krystal, AD; Laska, E; Roth, T; Walsh, JK; Wessel, TC, 2003)
"To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transient and chronic insomnia in adult and geriatric patients."4.82Eszopiclone for insomnia. ( Kirkwood, CK; Melton, ST; Wood, JM, 2005)
"Insomnia is a common condition in older adults and is associated with a number of adverse medical, social, and psychological consequences."2.72Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. ( Bjorvatn, B; Havik, OE; Kvale, G; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B, 2006)
"6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study."2.65Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1983)
"Tolerance or rebound insomnia was not reported."2.43Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. ( Najib, J, 2006)
"In total, 181 chronic insomnia patients were consecutively recruited."1.46Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months. ( Chen, H; He, J; Liu, Y; Luan, X; Qiu, H; Shen, H; Tu, X; Zhao, K; Zhu, Z, 2017)
"Alprazolam is a triazolobenzodiazepine derivative used as a tranquilizer."1.37Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. ( Antonescu, A; Bogdan, M; Dobjanschi, L; Moş, I; Mureşan, M; Muţiu, G; Zdrîncă, M, 2011)
"Thirty-four participants with chronic primary insomnia."1.33A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia. ( Bjorvatn, B; Havik, OE; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B; Straume, S, 2006)
"6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study."1.26Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1982)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19904 (16.00)18.7374
1990's3 (12.00)18.2507
2000's15 (60.00)29.6817
2010's3 (12.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, K1
Luan, X1
Liu, Y1
Tu, X1
Chen, H1
Shen, H1
Qiu, H1
Zhu, Z1
He, J1
Sivertsen, B3
Omvik, S3
Pallesen, S3
Nordhus, IH3
Bjorvatn, B3
Mets, MA1
Volkerts, ER1
Olivier, B1
Verster, JC1
Zdrîncă, M2
Muţiu, G1
Bogdan, M1
Dobjanschi, L1
Antonescu, A2
Moş, I1
Mureşan, M1
Krystal, AD1
Walsh, JK1
Laska, E1
Caron, J1
Amato, DA1
Wessel, TC1
Roth, T1
Jacobs, GD1
Kramer, M1
Vallières, A2
Morin, CM3
Guay, B2
Bastien, CH1
LeBlanc, M1
Melton, ST1
Wood, JM1
Kirkwood, CK1
Laustsen, G1
Najib, J1
Havik, OE2
Kvale, G1
Nielsen, GH2
Straume, S1
Lesser, GT1
Persaud, R1
Belleville, G1
Mamelak, M2
Scima, A2
Price, V2
Parker, G1
Roberts, CJ1
Kajimura, N1
Kato, M1
Okuma, T1
Onuma, T1
Veĭn, AM3
Levin, IaI2
Eligulashvili, TS2
Posokhov, SI2
Kovrov, GV2
Bashmakov, MIu1
Gasanov, RL1
Poluéktov, MG1
Fokin, IV1
Kolosova, OA1
Osipova, VV1
Agnoli, A1
Manna, V1
Martucci, N1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976]Phase 458 participants (Actual)Interventional2006-08-31Completed
[NCT00295386]Phase 40 participants Interventional2004-01-31Completed
Nightly Light Exposure in Pregnancy: Blue-blocking Glasses as an Intervention to Ease Sleep Disturbances and to Improve Mood[NCT03114072]60 participants (Anticipated)Interventional2017-06-06Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Depression Rating Scale (HAM-D-24)

The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4

,
Interventionunits on a scale (Mean)
prenaprosyn Baselinepostnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone6.456.384.544.142.62
Placebo7.106.575.535.076.21

Insomnia Severity Index (ISI)

The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
Prenaprosyn BaselinePostnaprosyn baselineWeek 1Week 2Week 4
Eszopiclone18.8518.0011.2810.618.38
Placebo20.2616.7812.8512.7413.75

Mean Sleep Onset Latency (SOL)

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionminutes (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone38.2822.3617.5015.28
Placebo34.1127.0023.1019.91

Mean Subjective Sleep Diary Derived Total Sleep Time (TST)

Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4

,
InterventionMinutes (Mean)
postnaprosyn baselineweek 1week 2Week 4
Eszopiclone316.96403.47421.97411.97
Placebo380.45375.56382.11388.96

Number of Awakenings

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionawakenings (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone2.291.311.351.33
Placebo2.081.982.132.34

Patient Global Impression of Pain Ratings

Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone4.023.543.303.08
Placebo3.903.824.013.80

Roland Morris Low Back Pain Inventory (RMLBPI)

"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4

,
Interventionunits on a scale (Mean)
prenaprosyn Baselinepostnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone12.279.979.107.636.59
Placebo11.3310.309.059.327.94

Sleep Quality Ratings

Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionunits on a scale (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone4.525.996.186.38
Placebo4.444.905.335.29

Visual Analog Scale Pain Ratings (VAS)

Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4

,
Interventionunits on a scale (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone48.5140.7234.7031.69
Placebo53.7951.9951.2551.60

Wake Time After Sleep Onset

(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4

,
Interventionminutes (Mean)
Postnaprosyn BaselineWeek 1Week 2Week 4
Eszopiclone91.5149.3437.0736.74
Placebo81.4376.7181.3276.18

Reviews

2 reviews available for zopiclone and Chronic Disease

ArticleYear
Eszopiclone for insomnia.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:10

    Topics: Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Humans; Hypnotics and Sedatives; ME

2005
Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Clinical therapeutics, 2006, Volume: 28, Issue:4

    Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio

2006

Trials

8 trials available for zopiclone and Chronic Disease

ArticleYear
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
    Sleep, 2003, Nov-01, Volume: 26, Issue:7

    Topics: Adult; Aged; Azabicyclo Compounds; Chronic Disease; Circadian Rhythm; Double-Blind Method; Female; H

2003
Sequential treatment for chronic insomnia: a pilot study.
    Behavioral sleep medicine, 2004, Volume: 2, Issue:2

    Topics: Adult; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therap

2004
Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study.
    Behaviour research and therapy, 2005, Volume: 43, Issue:12

    Topics: Adult; Azabicyclo Compounds; Behavior Therapy; Chronic Disease; Cognitive Behavioral Therapy; Combin

2005
Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial.
    JAMA, 2006, Jun-28, Volume: 295, Issue:24

    Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Double-Blind Method; Fema

2006
Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
    Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2008, Volume: 27, Issue:2

    Topics: Acetamides; Adaptation, Psychological; Adult; Aged; Anxiety; Attitude to Health; Azabicyclo Compound

2008
Effects of zopiclone on the sleep of chronic insomniacs.
    Pharmacology, 1983, Volume: 27 Suppl 2

    Topics: Adult; Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Electroencephalography; Fema

1983
[The clinical evaluation of the action of Imovane on patients with insomnia].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1994, Volume: 94, Issue:3

    Topics: Adolescent; Adult; Analysis of Variance; Azabicyclo Compounds; Chronic Disease; Cluster Analysis; Fe

1994
Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia.
    International journal of clinical pharmacology research, 1989, Volume: 9, Issue:4

    Topics: Adult; Anxiety Disorders; Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Double-Bl

1989

Other Studies

15 other studies available for zopiclone and Chronic Disease

ArticleYear
Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months.
    Clinica chimica acta; international journal of clinical chemistry, 2017, Volume: 475

    Topics: Adult; Antidepressive Agents; Azabicyclo Compounds; Biomarkers; Case-Control Studies; Chronic Diseas

2017
Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009, Aug-15, Volume: 5, Issue:4

    Topics: Azabicyclo Compounds; Case-Control Studies; Chronic Disease; Female; Humans; Hypnotics and Sedatives

2009
Effect of hypnotic drugs on body balance and standing steadiness.
    Sleep medicine reviews, 2010, Volume: 14, Issue:4

    Topics: Acetamides; Adult; Aged; Alcohol Drinking; Azabicyclo Compounds; Benzodiazepines; Chronic Disease; D

2010
Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2011, Volume: 52, Issue:1 Suppl

    Topics: Alprazolam; Animals; Azabicyclo Compounds; Chronic Disease; Granuloma, Foreign-Body; Inflammation; M

2011
Is Eszopiclone appropriate and effective for the long-term clinical management of chronic insomnia?
    Sleep, 2004, Mar-15, Volume: 27, Issue:2

    Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Long-Term Care; Piperazines;

2004
Hypnotic medication: shed light not heat!
    Sleep, 2004, Aug-01, Volume: 27, Issue:5

    Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio

2004
Eszopiclone (lunesta) for treatment of insomnia.
    The Nurse practitioner, 2005, Volume: 30, Issue:9

    Topics: Azabicyclo Compounds; Chronic Disease; Humans; Metabolic Clearance Rate; Patient Education as Topic;

2005
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
    Sleep, 2006, Volume: 29, Issue:10

    Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy

2006
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
    Sleep, 2006, Volume: 29, Issue:10

    Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy

2006
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
    Sleep, 2006, Volume: 29, Issue:10

    Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy

2006
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
    Sleep, 2006, Volume: 29, Issue:10

    Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy

2006
Treatment of chronic insomnia with cognitive behavioral therapy vs zopiclone.
    JAMA, 2006, Nov-22, Volume: 296, Issue:20

    Topics: Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives

2006
Treatment of chronic insomnia with cognitive behavioral therapy vs zopiclone.
    JAMA, 2006, Nov-22, Volume: 296, Issue:20

    Topics: Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives

2006
Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.
    British journal of clinical pharmacology, 1983, Volume: 16, Issue:3

    Topics: Adult; Aged; Azabicyclo Compounds; Central Nervous System Depressants; Chronic Disease; Electroencep

1983
Effects of zopiclone on the sleep of chronic insomniacs.
    International pharmacopsychiatry, 1982, Volume: 17 Suppl 2

    Topics: Adult; Azabicyclo Compounds; Chronic Disease; Electroencephalography; Female; Humans; Hypnotics and

1982
Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics.
    Progress in neuro-psychopharmacology & biological psychiatry, 1994, Volume: 18, Issue:3

    Topics: Adult; Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Chronic Disease; Humans; Hypnotic

1994
[The effect of Imovane on sleep structure and respiratory indices during sleep in insomnia patients].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Chronic Disease; Drug Evaluation;

1997
[Clinical and psychological characteristics and therapy of patients with cluster (bunch) headache].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2001, Volume: 101, Issue:10

    Topics: Adult; Azabicyclo Compounds; Chronic Disease; Cluster Headache; Female; Humans; Hypnotics and Sedati

2001